Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

@article{Burmester2013TofacitinibI,
  title={Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.},
  author={Gerd ‐ R{\"u}diger Burmester and Ricardo Blanco and Christina Charles-Schoeman and Juergen Wollenhaupt and Cristiano Zerbini and Birgitta Benda and David Gruben and Gene Wallenstein and Sriram Krishnaswami and Samuel H. Zwillich and Tam{\'a}s Koncz and Koshika Soma and John Bradley and Charles Mebus},
  journal={Lancet},
  year={2013},
  volume={381 9865},
  pages={451-60}
}
BACKGROUND Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. We investigated the effectiveness of tofacitinib (CP-690,550), a novel oral Janus kinase inhibitor, as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis. METHODS We did a 6-month, double-blind, parallel-group phase 3 study at 82 centres in 13 countries, including North America, Europe… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 184 extracted citations

Similar Papers

Loading similar papers…